4-chloro-N-(2-methyl-2,3-dihydro-1H-indol-3-yl)-3-sulfamoylbenzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-chloro-N-(2-methyl-2,3-dihydro-1H-indol-3-yl)-3-sulfamoylbenzamide
• 化学式: C₁₆H₁₆ClN₃O₃S
• 分子量: 365.8
• InChiKey: YJBVFLNZYKDXQA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  110
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY
  申请人：Anavex Life Sciences Corp.

  公开号：EP3716968A1

  公开（公告）日：2020-10-07
• [EN] COMPOSITIONS AND METHODS FOR TREATMENT OF RENAL DISEASE<br/>[FR] COMPOSITIONS ET MÉTHODES UTILISABLES DANS LE CADRE DU TRAITEMENT D'AFFECTIONS RÉNALES
  申请人：GUPTA AJAY

  公开号：WO2010111599A2

  公开（公告）日：2010-09-30

  The invention relates to methods, compositions, and kits for the treatment of proteinuria and/or hypertension (e.g., proteinuria and/or hypertension arising from primary renal disease (e.g., focal segmental glomerulosclerosis, glomerular disease) or secondary to other conditions (e.g., diabetes, diabetic nephropathy, liver disease). Specifically, the invention relates to methods involving combination therapy wherein an indoline (e.g., indapamide) is administered in combination with an anti-aldosterone agent (e.g., spironolactone and/or epleronone).